{
  "pmcid": "115849",
  "config": {
    "model": "gemini",
    "strategy": "few-shot"
  },
  "usage": {
    "input": 18656,
    "output": 4060
  },
  "raw_text": "```json\n{\"extractions\":[\n  {\n    \"outcome\": \"Discontinuation due to lack of efficacy\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"naproxen 500 mg twice daily\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": 353,\n    \"comparator_events\": null,\n    \"comparator_group_size\": 181,\n    \"intervention_mean\": 12.5,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": 10.5,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"patients discontinued due to lack of efficacy\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"binary\",\n    \"intervention_events\": 44,\n    \"intervention_group_size\": 353,\n    \"comparator_events\": 90,\n    \"comparator_group_size\": 357,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"patients discontinued due to lack of efficacy\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"binary\",\n    \"intervention_events\": 19,\n    \"intervention_group_size\": 181,\n    \"comparator_events\": 90,\n    \"comparator_group_size\": 357,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Patient global assessment of disease activity\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"investigator global assessment of disease activity\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Tender joint count\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Swollen joint count\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Patient global assessment of pain\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Health Assessment Questionnaire disability\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Serum C-reactive protein\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"ACR20 responder criteria\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": 353,\n    \"comparator_events\": null,\n    \"comparator_group_size\": 357,\n    \"intervention_mean\": 58.7,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": 40.9,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Discontinuation due to lack of efficacy\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": 353,\n    \"comparator_events\": null,\n    \"comparator_group_size\": 357,\n    \"intervention_mean\": 12.5,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": 25.2,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Patient global assessment of disease activity\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"investigator global assessment of disease activity\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Tender joint count\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Swollen joint count\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Patient global assessment of pain\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Health Assessment Questionnaire disability\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Serum C-reactive protein\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"ACR20 responder criteria\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": 181,\n    \"comparator_events\": null,\n    \"comparator_group_size\": 357,\n    \"intervention_mean\": 57.5,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": 40.9,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Discontinuation due to lack of efficacy\",\n    \"intervention\": \"naproxen 500 mg twice daily\",\n    \"comparator\": \"placebo\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": 181,\n    \"comparator_events\": null,\n    \"comparator_group_size\": 357,\n    \"intervention_mean\": 10.5,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": 25.2,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Patient global assessment of disease activity\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"naproxen 500 mg twice daily\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"investigator global assessment of disease activity\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"naproxen 500 mg twice daily\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Tender joint count\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"naproxen 500 mg twice daily\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Swollen joint count\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"naproxen 500 mg twice daily\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Patient global assessment of pain\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"naproxen 500 mg twice daily\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Health Assessment Questionnaire disability\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"naproxen 500 mg twice daily\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"Serum C-reactive protein\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"naproxen 500 mg twice daily\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": null,\n    \"comparator_events\": null,\n    \"comparator_group_size\": null,\n    \"intervention_mean\": null,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": null,\n    \"comparator_standard_deviation\": null\n  },\n  {\n    \"outcome\": \"ACR20 responder criteria\",\n    \"intervention\": \"etoricoxib 90 mg once daily\",\n    \"comparator\": \"naproxen 500 mg twice daily\",\n    \"outcome_type\": \"continuous\",\n    \"intervention_events\": null,\n    \"intervention_group_size\": 353,\n    \"comparator_events\": null,\n    \"comparator_group_size\": 181,\n    \"intervention_mean\": 58.7,\n    \"intervention_standard_deviation\": null,\n    \"comparator_mean\": 57.5,\n    \"comparator_standard_deviation\": null\n  }\n]}\n```",
  "extraction": [
    {
      "outcome": "Discontinuation due to lack of efficacy",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "naproxen 500 mg twice daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 353,
      "comparator_events": null,
      "comparator_group_size": 181,
      "intervention_mean": 12.5,
      "intervention_standard_deviation": null,
      "comparator_mean": 10.5,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "patients discontinued due to lack of efficacy",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "binary",
      "intervention_events": 44,
      "intervention_group_size": 353,
      "comparator_events": 90,
      "comparator_group_size": 357,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "patients discontinued due to lack of efficacy",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "binary",
      "intervention_events": 19,
      "intervention_group_size": 181,
      "comparator_events": 90,
      "comparator_group_size": 357,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Patient global assessment of disease activity",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "investigator global assessment of disease activity",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Tender joint count",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Swollen joint count",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Patient global assessment of pain",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Health Assessment Questionnaire disability",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Serum C-reactive protein",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "ACR20 responder criteria",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 353,
      "comparator_events": null,
      "comparator_group_size": 357,
      "intervention_mean": 58.7,
      "intervention_standard_deviation": null,
      "comparator_mean": 40.9,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Discontinuation due to lack of efficacy",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 353,
      "comparator_events": null,
      "comparator_group_size": 357,
      "intervention_mean": 12.5,
      "intervention_standard_deviation": null,
      "comparator_mean": 25.2,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Patient global assessment of disease activity",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "investigator global assessment of disease activity",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Tender joint count",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Swollen joint count",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Patient global assessment of pain",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Health Assessment Questionnaire disability",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Serum C-reactive protein",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "ACR20 responder criteria",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 181,
      "comparator_events": null,
      "comparator_group_size": 357,
      "intervention_mean": 57.5,
      "intervention_standard_deviation": null,
      "comparator_mean": 40.9,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Discontinuation due to lack of efficacy",
      "intervention": "naproxen 500 mg twice daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 181,
      "comparator_events": null,
      "comparator_group_size": 357,
      "intervention_mean": 10.5,
      "intervention_standard_deviation": null,
      "comparator_mean": 25.2,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Patient global assessment of disease activity",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "naproxen 500 mg twice daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "investigator global assessment of disease activity",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "naproxen 500 mg twice daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Tender joint count",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "naproxen 500 mg twice daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Swollen joint count",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "naproxen 500 mg twice daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Patient global assessment of pain",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "naproxen 500 mg twice daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Health Assessment Questionnaire disability",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "naproxen 500 mg twice daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "Serum C-reactive protein",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "naproxen 500 mg twice daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    },
    {
      "outcome": "ACR20 responder criteria",
      "intervention": "etoricoxib 90 mg once daily",
      "comparator": "naproxen 500 mg twice daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 353,
      "comparator_events": null,
      "comparator_group_size": 181,
      "intervention_mean": 58.7,
      "intervention_standard_deviation": null,
      "comparator_mean": 57.5,
      "comparator_standard_deviation": null,
      "pmcid": "115849"
    }
  ]
}